Abstract
Pruritus (itch) is a major symptom of several dermatological diseases but has limited therapeutic options available. Itch stimuli are transmitted via primary sensory neurons in the skin by activating pruriceptors/nociceptors on small unmyelinated C-fibers, through the spinal cord for final processing in the brain. CLE-400 is an aqueous gel of detomidine that is being developed for the topical treatment of itch. Detomidine is a potent α2-adrenergic receptor (α2-AR) agonist. α2-AR have been shown to be expressed on skin nociceptors and their activation by topical administration of detomidine could lead to inhibition of itch neural signalling.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
